Scientific publications

Estrogen Receptor and Immune Checkpoint Inhibitors: New Partners in Lung Cancer?

Oct 2, 2023 | Magazine: Clinical Cancer Research

Karmele Valencia 1 2 3 4 5, Luis M Montuenga 1 2 3 5 6, Alfonso Calvo 1 2 3 5 6

Abstract

The influence of sex on immunotherapy response in patients with non-small cell lung cancer (NSCLC) had been studied with no clear conclusions. An article in this issue reports that a key determinant of response is not sex but the existence of a 17β-estradiol/ERα/PDL1 signaling loop in NSCLC. This intriguing result opens new therapeutic options. See related article by Anobile et al., p. 3958.

CITA DEL ARTÍCULO: Clin Cancer Res. 2023 Oct 2;29(19):3832-3834. doi: 10.1158/1078-0432.CCR-23-1736.

see publication in pubmed

Our authors

Dr. Karmele Valencia Leoz Curriculum
Researcher | Principal Investigator Therapeutic Innovation in Lung Cancer research group
Dr. Luis Montuenga Badía Curriculum
Researcher | Principal Investigator Research Group Lungsearch: Lung cancer Screening, Early detection, biomarkers and new therapeutic targets
Dr. Alfonso Calvo González
Researcher Research Group Lungsearch: Lung cancer Screening, Early detection, biomarkers and new therapeutic targets